Navigation Links
Brookhaven scientists explore brain's reaction to potent hallucinogen
Date:4/28/2008

UPTON, NY - Brain-imaging studies performed in animals at the U.S. Department of Energys (DOE) Brookhaven National Laboratory provide researchers with clues about why an increasingly popular recreational drug that causes hallucinations and motor-function impairment in humans is abused. Using trace amounts of Salvia divinorum also known as salvia, a Mexican mint plant that can be smoked in the form of dried leaves or serum Brookhaven scientists found that the drugs behavior in the brains of primates mimics the extremely fast and brief high observed in humans. Their results are now published online in the journal NeuroImage.

Quickly gaining popularity among teenagers and young adults, salvia is legal in most states, but is grabbing the attention of municipal lawmakers. Numerous states have placed controls on salvia or salvinorin A the plants active component and others, including New York, are considering restrictions.

This is probably one of the most potent hallucinogens known, said Brookhaven chemist Jacob Hooker, the lead author of the study, which is the first to look at how the drug travels through the brain. Its really important that we study drugs like salvia and how they affect the brain in order to understand why they are abused and to investigate their medicinal relevance, both of which can inform policy makers.

Hooker and fellow researchers used positron emission tomography, or PET scanning, to watch the distribution of salvinorin A in the brains of anesthetized primates. In this technique, the scientists administer a radioactively labeled form of salvinorin A (at concentrations far below pharmacologically active doses) and use the PET scanner to track its site-specific concentrations in various brain regions.

Within 40 seconds of administration, the researchers found a peak concentration of salvinorin A in the brain nearly 10 times faster than the rate at which cocaine enters the brain. About 16 minutes later, the drug was essentially gone. This pattern parallels the effects described by human users, who experience an almost immediate high that starts fading away within 5 to 10 minutes.

High concentrations of the drug were localized to the cerebellum and visual cortex, which are parts of the brain responsible for motor function and vision, respectively. Based on their results and published data from human use, the scientists estimate that just 10 micrograms of salvia in the brain is needed to cause psychoactive effects in humans.

Salvia doesnt cause the typical euphoric state associated with other hallucinogens like LSD, Hooker said. The drug targets a receptor that is known to modulate pain and could be important for therapies as far reaching as mood disorders.

Most people dont find this class of drugs very pleasurable, Hooker said. So perhaps the main draw or reason for its appeal relates to the rapid onset and short duration of its effects, which are incredibly unique. The kinetics are often as important as the abused drug itself.

The Brookhaven team plans to conduct further studies related to salvias abuse potential. The scientists also hope to develop radioactive tracers that can better probe the brain receptors to which salvia binds. Such studies could possibly lead to therapies for chronic pain and mood disorders.


'/>"/>

Contact: Kendra Snyder
ksnyder@bnl.gov
631-344-8191
DOE/Brookhaven National Laboratory
Source:Eurekalert

Related medicine news :

1. Scientists Discover How Stomach Tumors Form
2. U.S. Scientists Receive Japan Prize on April 23, 2008
3. Scientists discover a mechanism that can send cells on the road to cancer
4. Scientists identify novel way to prevent cardiac fibrosis
5. Scientists Explore Human Gene Pool With Help From Microsoft Research
6. Scientists obtain anticancer medicines from the elecampe, a wild plant growing in the Mediterranean
7. Jefferson scientists discovery may help explain smoking-pancreatic cancer link
8. With annual deaths from malaria on the rise: Scientists ask where is all the money going?
9. Stem cells and cancer: Scientists investigate a fine balancing act
10. Scientists Block Prostate Cancer Cells Spread
11. Scientists solve mystery of polyketide drug formation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/10/2016)... (PRWEB) , ... December 10, 2016 , ... When faced ... worried about germs spreading from the seat to her body, and contamination of children ... and effective way to solve this problem that many people face. , The patent-pending ...
(Date:12/9/2016)... (PRWEB) , ... December 09, 2016 , ... ... planning assistance from offices in Pasco and Richland, is initiating a charity drive ... serious injuries resulting from a recent automobile collision. , On October 29th ...
(Date:12/9/2016)... ... December 09, 2016 , ... ... pharmaceutical inserts and outserts. As a means of expanding capabilities Flottman has ... enable Flottman to individually code professional inserts (PIs) and patient package inserts (PPIs) ...
(Date:12/9/2016)... ... 09, 2016 , ... The Justin Veatch Fund announced Thursday that ... the film Whispering Spirits and its discussion guide for use by all ... tool in the war against teen drug abuse. NCADD is the oldest anti-addiction ...
(Date:12/9/2016)... ... December 09, 2016 , ... An inventor from Cana, Va., wanted ... all types of amusement park rides. , The patent-pending SAFETY STRAP FOR AMPUTEES improves ... use and could be set up in a matter of minutes, or even seconds. ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... 2016 Research and Markets has announced the addition of ... offering. ... This report analyzes the worldwide markets for Endodontic Supplies in US$ Thousand. ... , Japan , Europe , ... Annual estimates and forecasts are provided for the period 2015 through ...
(Date:12/8/2016)... 8, 2016   TriNetX , the health ... Hospital signed a membership agreement to join ... of new cures. The TriNetX network ... million patients globally, biopharmaceutical companies and contract research ... protocol design, site selection, patient recruitment, and collaborative ...
(Date:12/8/2016)... LAVAL, Quebec , Dec. 8, 2016 /PRNewswire/ ... and TSX: VRX) ("Valeant") today announced positive ... vehicle-controlled clinical study to assess the safety and ... in the treatment of plaque psoriasis. ... adult subjects with moderate to severe psoriasis, IDP-118 ...
Breaking Medicine Technology: